ClinicalTrials.gg
CompletedNCT00740246Updated Apr 18, 2025Results posted

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

A Phase 3 interventional study of VIT-45 and Placebo in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Jul 2005, registered Aug 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
8th of 54
594 · median 156
Started
2005
with 4 others
Phase 3
23 of 54
none open now
Registered
12th of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 8th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 12th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia

Read the detailed description

Evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects > or = 18 years of age and able to give
  • Historical laboratory indicative of anemia within 3 months prior to screening visit
  • Screening Visit laboratory Hgb indicative of anemia
  • Screening Visit ferritin indicative of iron deficiency anemia

Exclusion criteria

Exclusion Criteria:

  • Known to VIT-45
  • Previously received VIT-45
  • Parenteral iron in the 4 weeks prior to screening
  • Chronic or serious active infection
  • history
  • (AST) or Alanine transaminase( ALT) greater than the
  • Anticipated need for surgery or initiation of dialysis during the study
  • Pregnant or sexually active females who are not willing to use an effective form of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
594 participants (actual)

Study arms

  • Experimental
    VIT-45 on Day 0, then Placebo on Day 7

    Day 0: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously. Day 7: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously.

    Drug: VIT-45 · Drug: Placebo

  • Experimental
    Placebo on Day 0, then VIT-45 on Day 7

    Day 0: for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously. Day 7: 15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously.

    Drug: VIT-45 · Drug: Placebo

Interventions

  • DrugVIT-45

    15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously

    Also known as: ferric carboxymaltose

  • DrugPlacebo

    for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period

    Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.

    Time frame: Day 0 to 7

07

Results

Posted Apr 18, 2025

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneVIT-45/PlaceboPlacebo/VIT-045
Started305289
Completed291277
Not completed1412
Withdrew: Received blood transfusion01
Withdrew: Adverse event12
Withdrew: Selection criteria/study compliance20
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject43
Withdrew: Withdrawn by site due to non-compliance10
Withdrew: Discontinued due to hurricane related issue11
Withdrew: Unable to perform venipuncture for day 7, day 14 labs, and day 7 infusion10
Withdrew: Unable to comply with study visits20
Withdrew: Unable to access vein02
Withdrew: Early term - patient could not return for second infusion due to thanksgiving holiday01

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events During Each 7-day Study Period

Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.

Time frame:
Day 0 to 7
Reported as:
Number · participants
Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period
participantsViT-45Placebo
Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period174114

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VIT-45 on Day 0 or Day 71/584 (0.2%)2/584 (0.3%)31/584 (5.3%)
Placebo on Day 0 or Day 70/569 (0%)4/569 (0.7%)19/569 (3.3%)
Most frequent serious events
Most frequent serious events
EventVIT-45 on Day 0 or Day 7Placebo on Day 0 or Day 7
Diabetes mellitus non-insulin dependentMetabolism and nutrition disorders0/5841/569
HypertensionVascular disorders0/5841/569
Upper gastrointestinal hemorrhageGastrointestinal disorders0/5841/569
PneumothoraxRespiratory, thoracic and mediastinal disorders0/5841/569
EndometritisInfections and infestations0/5841/569
FallInjury, poisoning and procedural complications0/5841/569
PneumoniaInfections and infestations1/5840/569
Intestinal obstructionGastrointestinal disorders1/5840/569
Most frequent other events
Most frequent other events
EventVIT-45 on Day 0 or Day 7Placebo on Day 0 or Day 7
HeadacheNervous system disorders31/58419/569

Baseline characteristics

Safety population: All subjects who received at least 1 dose of randomized study drug

Age, Continuous
Age, Continuous(years)VIT-45PlaceboTotal
Mean41.2 ± 16.432542.6 ± 16.929641.9 ± 16.6767
Sex: Female, Male
Sex: Female, Male(Participants)VIT-45PlaceboTotal
Female363470
Male269255524
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VIT-45PlaceboTotal
American Indian or Alaska Native000
Asian4952101
Native Hawaiian or Other Pacific Islander000
Black or African American190178368
White6248110
More than one race000
Unknown or Not Reported41115
Region of Enrollment
Region of Enrollment(participants)VIT-45PlaceboTotal
United States305289594
Weight
Weight(kilograms)VIT-45PlaceboTotal
Mean80.6 ± 80.680.6 ± 80.680.6 ± 8.6
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

References and documents

Publications

  • Seid MH, Valaoras TG, Barish CF, Dinh Q. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.
  • Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Feb 2006, 7 months.

Results were first posted in Apr 2025, 19 years 2 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 7 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2008
First posted
Aug 22, 2008
StartActual
Jul 2005
Primary completionActual
Feb 2006
CompletionActual
May 2006
Results first posted
Apr 18, 2025
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00740246
Responsible party
Sponsor
First posted
Aug 22, 2008
Start date
Jul 2005
Primary completion
Feb 2006
Completion
May 2006
Results posted
Apr 18, 2025
Last update
Apr 18, 2025

Study contacts

David Bregman, MD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion